secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-278835
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Q3 net loss $16.3M; cash $103.8M; vilastobart 40% ORR in MSS mCRC subset
------------------------------------------------------------------------------

- Net loss $16.3M for Q3 2025 vs $14.0M in Q3 2024; collaboration revenue $19.1M (up from $2.3M YoY).
- Cash $103.8M at Sep 30, 2025; plus $17.5M milestone from Gilead in Q4; runway into Q1 2027.
- Vilastobart Phase 2 data: 40% ORR in heavily pretreated MSS mCRC without liver metastases and high plasma TMB (≥10 mut/Mb).
- Efarindodekin alfa Phase 1 data showed monotherapy activity; RP2D selected; $17.5M milestone from Gilead achieved.
- XTX501 IND planned mid-2026; masked T cell engagers advancing with PSMA, CLDN18.2, STEAP1 candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312525278835/0001193125-25-278835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312525278835/xlo-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-278835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer